Tagrisso

Tagrisso (osimertinib) is an oral medication used to treat certain types of non-small cell lung cancer. This targeted therapy helps slow cancer progression by blocking abnormal signals in cancer cells. Suitable for patients with specific genetic mutations, it is prescribed under medical supervision.

Tagrisso (osimertinib) is primarily used to treat non-small cell lung cancer (NSCLC) in patients with specific genetic mutations, such as EGFR T790M. It may also be prescribed for other EGFR mutation-positive lung cancers as determined by a healthcare provider. This medication is designed to target cancer cells while minimizing damage to healthy cells.

Tagrisso (osimertinib) works by interfering with signals that promote cancer cell growth, helping to slow or stop tumor progression. Patients may experience improved symptoms related to lung cancer, such as reduced coughing or shortness of breath. Individual responses vary, and effects should be monitored by a healthcare professional.

Tagrisso should be taken exactly as prescribed by a doctor, typically once daily. Patients should inform their healthcare provider about all medications, supplements, and medical conditions before starting treatment. Regular check-ups and monitoring may be required to assess effectiveness and manage side effects.

Certain medications, including strong CYP3A4 inhibitors or inducers, may interact with Tagrisso, potentially affecting its effectiveness or increasing side effects. Patients should avoid grapefruit products while taking this medication. Alcohol use and other drugs should be discussed with a healthcare provider to prevent adverse interactions.